In vitro assessment of the allelic variants of cytochrome P450

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 1, 2012, Pages 68-84

  Hiratsuka, Masahiro ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Allelic variant; Cytochrome P450; Genetic polymorphism; In vitro; Kinetic parameter; Pharmacogenetics; SNP

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACENOCOUMAROL; AMITRIPTYLINE; ARACHIDONIC ACID; ATOMOXETINE; BUFURALOL; CELECOXIB; CODEINE; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DEBRISOQUINE; DEXTROMETHORPHAN; DICLOFENAC; FLUOXETINE; FLURBIPROFEN; IFOSFAMIDE; LOSARTAN; MEFENAMIC ACID; METOPROLOL; NORTRIPTYLINE; PHENYTOIN; PIROXICAM; SERATRODAST; TENOXICAM; TOLBUTAMIDE; TRAMADOL; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

ALLELE; BACTERIUM; BACULOVIRUS; CYP1A1 GENE; CYP1A2 GENE; CYP2B6 GENE; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP2E1 GENE; CYP3A4 GENE; DRUG CLEARANCE; DRUG METABOLISM; ENZYME SUBSTRATE; GENE EXPRESSION SYSTEM; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENETIC CONSERVATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROLOGOUS EXPRESSION; IN VITRO STUDY; MAMMAL CELL; MARKER GENE; NONHUMAN; PHENOTYPE; RECOMBINANT GENE; REVIEW; YEAST;

EID: 84857705942     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RV-090     Document Type: Review

References (109)

1. Ingelman-Sundberg, M., Sim, S. C., Gomez, A. and Rodriguez-Antona, C.: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther., 116: 496-526 (2007).
2. Johansson, I. and Ingelman-Sundberg, M.: Genetic polymorphism and toxicology-with emphasis on cytochrome p450. Toxicol. Sci., 120: 1-13 (2011).
3. Evans, W. E. and Relling, M. V.: Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286: 487-491 (1999).
4. Goldstein, D. B., Tate, S. K. and Sisodiya, S. M.: Pharmacogenetics goes genomic. Nat. Rev. Genet., 4: 937-947 (2003).
5. Bertz, R. J. and Granneman, G. R.: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet., 32: 210-258 (1997).
6. Chen, S., Zhou, D., Swiderek, K. M., Kadohama, N., Osawa, Y. and Hall, P. F.: Structure-function studies of human aromatase. J. Steroid Biochem. Mol. Biol., 44: 347-356 (1993).
7. Gomez, A., Nekvindova, J., Travica, S., Lee, M. Y., Johansson, I., Edler, D., Mkrtchian, S. and Ingelman-Sundberg, M.: Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity. Mol. Pharmacol., 78: 1004-1011 (2010).
8. Sethumadhavan, K., Bellino, F. L. and Thotakura, N. R.: Estrogen synthetase (aromatase). The cytochrome P-450 component of the human placental enzyme is a glycoprotein. Mol. Cell. Endocrinol., 78: 25-32 (1991).
9. Shimozawa, O., Sakaguchi, M., Ogawa, H., Harada, N., Mihara, K. and Omura, T.: Core glycosylation of cytochrome P-450(arom). Evidence for localization of N terminus of microsomal cytochrome P-450 in the lumen. J. Biol. Chem., 268: 21399-21402 (1993).
10. Koch, J. A. and Waxman, D. J.: P450 phosphorylation in isolated hepatocytes and in vivo. Methods Enzymol., 206: 305-315 (1991).
11. Menez, J. F., Machu, T. K., Song, B. J., Browning, M. D. and Deitrich, R. A.: Phosphorylation of cytochrome P4502E1 (CYP2E1) by calmodulin dependent protein kinase, protein kinase C and cAMP dependent protein kinase. Alcohol Alcohol., 28: 445-451 (1993).
12. Barnes, H. J., Arlotto, M. P. and Waterman, M. R.: Expression and enzymatic activity of recombinant cytochrome P450 17 alphahydroxylase in Escherichia coli. Proc. Natl. Acad. Sci. USA, 88: 5597-5601 (1991).
13. Gillam, E. M., Guo, Z. and Guengerich, F. P.: Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties. Arch. Biochem. Biophys., 312: 59-66 (1994).
14. Gillam, E. M., Guo, Z., Martin, M. V., Jenkins, C. M. and Guengerich, F. P.: Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization. Arch. Biochem. Biophys., 319: 540-550 (1995).
15. Gillam, E. M., Guo, Z., Ueng, Y. F., Yamazaki, H., Cock, I., Reilly, P. E., Hooper, W. D. and Guengerich, F. P.: Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch. Biochem. Biophys., 317: 374-384 (1995).
16. Guo, Z., Gillam, E. M., Ohmori, S., Tukey, R. H. and Guengerich, F. P.: Expression of modified human cytochrome P450 1A1 in Escherichia coli: effects of 5' substitution, stabilization, purification, spectral characterization, and catalytic properties. Arch. Biochem. Biophys., 312: 436-446 (1994).
17. Richardson, T. H., Jung, F., Griffin, K. J., Wester, M., Raucy, J. L., Kemper, B., Bornheim, L. M., Hassett, C., Omiecinski, C. J. and Johnson, E. F.: A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch. Biochem. Biophys., 323: 87-96 (1995).
18. Sandhu, P., Baba, T. and Guengerich, F. P.: Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Arch. Biochem. Biophys., 306: 443-450 (1993).
19. Sandhu, P., Guo, Z., Baba, T., Martin, M. V., Tukey, R. H. and Guengerich, F. P.: Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification, spectral characterization, and catalytic activities of the enzyme. Arch. Biochem. Biophys., 309: 168-177 (1994).
20. Oeda, K., Sakaki, T. and Ohkawa, H.: Expression of rat liver cytochrome P-450MC cDNA in Saccharomyces cerevisiae. DNA, 4: 203-210 (1985).
21. Murakami, H., Yabusaki, Y. and Ohkawa, H.: Expression of rat NADPH-cytochrome P-450 reductase cDNA in Saccharomyces cerevisiae. DNA, 5: 1-10 (1986).
22. Uno, T. and Imai, Y.: Identification of regions functioning in substrate interaction of rabbit liver cytochrome P-450 (laurate (omega-1)-hydroxylase). J. Biochem., 106: 569-574 (1989).
23. Iwasaki, M., Darden, T. A., Parker, C. E., Tomer, K. B., Pedersen, L. G. and Negishi, M.: Inherent versatility of P-450 oxygenase. Conferring dehydroepiandrosterone hydroxylase activity to P-450 2a-4 by a single amino acid mutation at position 117. J. Biol. Chem., 269: 9079-9083 (1994).
24. Asseffa, A., Smith, S. J., Nagata, K., Gillette, J., Gelboin, H. V. and Gonzalez, F. J.: Novel exogenous heme-dependent expression of mammalian cytochrome P450 using baculovirus. Arch. Biochem. Biophys., 274: 481-490 (1989).
25. Gonzalez, F. J., Kimura, S., Tamura, S. and Gelboin, H. V.: Expression of mammalian cytochrome P450 using baculovirus. Methods Enzymol., 206: 93-99 (1991).
26. Higashi, Y. and Fujii-Kuriyama, Y.: Functional analysis of mutant P450(C21) genes in COS cell expression system. Methods Enzymol., 206: 166-173 (1991).
27. Ingelman-Sundberg, M., Oscarson, M. and McLellan, R. A.: Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci., 20: 342-349 (1999).
28. Kronbach, T., Larabee, T. M. and Johnson, E. F.: Hybrid cytochromes P-450 identify a substrate binding domain in P-450IIC5 and P-450IIC4. Proc. Natl. Acad. Sci. USA, 86: 8262-8265 (1989).
29. Luo, Z., He, Y. A. and Halpert, J. R.: Role of residues 363 and 206 in conversion of cytochrome P450 2B1 from a steroid 16- hydroxylase to a 15 alpha-hydroxylase. Arch. Biochem. Biophys., 309: 52-57 (1994).
30. Minowa, O., Sogawa, K., Higashi, Y. and Fujii-Kuriyama, Y.: Functional expression of microsomal and mitochondrial cytochrome P-450 (d and SCC) in COS-7 cells from cloned cDNA. Cell Struct. Funct., 15: 21-30 (1990).
31. Kusano, K., Sakaguchi, M., Kagawa, N., Waterman, M. R. and Omura, T.: Microsomal p450s use specific proline-rich sequences for efficient folding, but not for maintenance of the folded structure. J. Biochem., 129: 259-269 (2001).
32. Chida, M., Yokoi, T., Nemoto, N., Inaba, M., Kinoshita, M. and Kamataki, T.: A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype. Pharmacogenetics, 9: 287-293 (1999).
33. Nishida, Y., Fukuda, T., Yamamoto, I. and Azuma, J.: CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics, 10: 567-570 (2000).
34. Koyama, E., Sohn, D. R., Shin, S. G., Chiba, K., Shin, J. G., Kim, Y. H., Echizen, H. and Ishizaki, T.: Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alphahydroxylation and S-mephenytoin 4'-hydroxylation phenotypes. J. Pharmacol. Exp. Ther., 271: 860-867 (1994).
35. Daly, A. K., Brockmoller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer, U. A., Nebert, D. W., Steen, V. M., Wolf, C. R. and Zanger, U. M.: Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 6: 193-201 (1996).
36. Johansson, I., Oscarson, M., Yue, Q. Y., Bertilsson, L., Sjoqvist, F. and Ingelman-Sundberg, M.: Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol., 46: 452-459 (1994).
37. Takahashi, H., Kashima, T., Nomoto, S., Iwade, K., Tainaka, H., Shimizu, T., Nomizo, Y., Muramoto, N., Kimura, S. and Echizen, H.: Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics, 8: 365-373 (1998).
38. Takanashi, K., Tainaka, H., Kobayashi, K., Yasumori, T., Hosakawa, M. and Chiba, K.: CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics, 10: 95-104 (2000).
39. Maekawa, K., Harakawa, N., Sugiyama, E., Tohkin, M., Kim, S. R., Kaniwa, N., Katori, N., Hasegawa, R., Yasuda, K., Kamide, K., Miyata, T., Saito, Y. and Sawada, J.: Substratedependent functional alterations of seven CYP2C9 variants found in Japanese subjects. Drug Metab. Dispos., 37: 1895-1903 (2009).
40. Kimura, M., Ieiri, I., Mamiya, K., Urae, A. and Higuchi, S.: Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug Monit., 20: 243-247 (1998).
41. Ieiri, I., Kubota, T., Urae, A., Kimura, M., Wada, Y., Mamiya, K., Yoshioka, S., Irie, S., Amamoto, T., Nakamura, K., Nakano, S. and Higuchi, S.: Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Clin. Pharmacol. Ther., 59: 647-653 (1996).
42. Furuta, T., Ohashi, K., Kosuge, K., Zhao, X. J., Takashima, M., Kimura, M., Nishimoto, M., Hanai, H., Kaneko, E. and Ishizaki, T.: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther., 65: 552-561 (1999).
43. Wang, H., An, N., Gao, Y., Liu, D., Bian, T., Zhu, J. and Chen, C.: Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'- hydroxylation and omeprazole 5'-hydroxylation. Drug Metab. Dispos., 39: 830-837 (2011).
44. Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I. and Greenblatt, D. J.: CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos., 28: 1176-1183 (2000).
45. Hidestrand, M., Oscarson, M., Salonen, J. S., Nyman, L., Pelkonen, O., Turpeinen, M. and Ingelman-Sundberg, M.: CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinsonös disease, as revealed from experiments with recombinant enzymes. Drug Metab. Dispos., 29: 1480-1484 (2001).
46. Roy, P., Yu, L. J., Crespi, C. L. and Waxman, D. J.: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab. Dispos., 27: 655-666 (1999).
47. Salonen, J. S., Nyman, L., Boobis, A. R., Edwards, R. J., Watts, P., Lake, B. G., Price, R. J., Renwick, A. B., Gomez-Lechon, M. J., Castell, J. V., Ingelman-Sundberg, M., Hidestrand, M., Guillouzo, A., Corcos, L., Goldfarb, P. S., Lewis, D. F., Taavitsainen, P. and Pelkonen, O.: Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab. Dispos., 31: 1093-1102 (2003).
48. Jinno, H., Tanaka-Kagawa, T., Ohno, A., Makino, Y., Matsushima, E., Hanioka, N. and Ando, M.: Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos., 31: 398-403 (2003).
49. Lang, T., Klein, K., Richter, T., Zibat, A., Kerb, R., Eichelbaum, M., Schwab, M. and Zanger, U. M.: Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J. Pharmacol. Exp. Ther., 311: 34-43 (2004).
50. Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W. H., Eichelbaum, M., Schwab, M. and Zanger, U. M.: Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics, 15: 861-873 (2005).
51. Rotger, M., Saumoy, M., Zhang, K., Flepp, M., Sahli, R., Decosterd, L. and Telenti, A.: Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. Pharmacogenet. Genomics, 17: 885-890 (2007).
52. Watanabe, T., Sakuyama, K., Sasaki, T., Ishii, Y., Ishikawa, M., Hirasawa, N. and Hiratsuka, M.: Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22). Pharmacogenet. Genomics, 20: 459-462 (2010).
53. Honda, M., Muroi, Y., Tamaki, Y., Saigusa, D., Suzuki, N., Tomioka, Y., Matsubara, Y., Oda, A., Hirasawa, N. and Hiratsuka, M.: Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether. Drug Metab. Dispos., 39: 1860-1865 (2011).
54. Wennerholm, A., Johansson, I., Hidestrand, M., Bertilsson, L., Gustafsson, L. L. and Ingelman-Sundberg, M.: Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics, 11: 417-427 (2001).
55. Zanger, U. M., Fischer, J., Raimundo, S., Stuven, T., Evert, B. O., Schwab, M. and Eichelbaum, M.: Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics, 11: 573-585 (2001).
56. Ramamoorthy, Y., Yu, A. M., Suh, N., Haining, R. L., Tyndale, R. F. and Sellers, E. M.: Reduced (+/-)-3,4-methylenedioxymethamphetamine (úEcstasyû) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem. Pharmacol., 63: 2111-2119 (2002).
57. Bapiro, T. E., Hasler, J. A., Ridderstrom, M. and Masimirembwa, C. M.: The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem. Pharmacol., 64: 1387-1398 (2002).
58. Marcucci, K. A., Pearce, R. E., Crespi, C., Steimel, D. T., Leeder, J. S. and Gaedigk, A.: Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab. Dispos., 30: 595-601 (2002).
59. Yu, A., Kneller, B. M., Rettie, A. E. and Haining, R. L.: Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J. Pharmacol. Exp. Ther., 303: 1291-1300 (2002).
60. Sakuyama, K., Sasaki, T., Ujiie, S., Obata, K., Mizugaki, M., Ishikawa, M. and Hiratsuka, M.: Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab. Dispos., 36: 2460-2467 (2008).
61. Kagimoto, M., Heim, M., Kagimoto, K., Zeugin, T. and Meyer, U. A.: Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J. Biol. Chem., 265: 17209-17214 (1990).
62. Evert, B., Eichelbaum, M., Haubruck, H. and Zanger, U. M.: Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells. Naunyn Schmiedebergs Arch. Pharmacol., 355: 309-318 (1997).
63. Fukuda, T., Nishida, Y., Imaoka, S., Hiroi, T., Naohara, M., Funae, Y. and Azuma, J.: The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch. Biochem. Biophys., 380: 303-308 (2000).
64. Ramamoorthy, Y., Tyndale, R. F. and Sellers, E. M.: Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics, 11: 477-487 (2001).
65. Nakamura, K., Ariyoshi, N., Yokoi, T., Ohgiya, S., Chida, M., Nagashima, K., Inoue, K., Kodama, T., Shimada, N. and Kamataki, T.: CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. Biochem. Biophys. Res. Commun., 293: 969-973 (2002).
66. Hanioka, N., Okumura, Y., Saito, Y., Hichiya, H., Soyama, A., Saito, K., Ueno, K., Sawada, J. and Narimatsu, S.: Catalytic roles of CYP2D6.10 and CYP2D6.36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae. Biochem. Pharmacol., 71: 1386-1395 (2006).
67. Shen, H., He, M. M., Liu, H., Wrighton, S. A., Wang, L., Guo, B. and Li, C.: Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos., 35: 1292-1300 (2007).
68. Matsunaga, M., Yamazaki, H., Kiyotani, K., Iwano, S., Saruwatari, J., Nakagawa, K., Soyama, A., Ozawa, S., Sawada, J., Kashiyama, E., Kinoshita, M. and Kamataki, T.: Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese. Drug Metab. Dispos., 37: 699-701 (2009).
69. Bogni, A., Monshouwer, M., Moscone, A., Hidestrand, M., Ingelman-Sundberg, M., Hartung, T. and Coecke, S.: Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. Toxicol. In Vitro, 19: 621-629 (2005).
70. Yokoi, T., Kosaka, Y., Chida, M., Chiba, K., Nakamura, H., Ishizaki, T., Kinoshita, M., Sato, K., Gonzalez, F. J. and Kamataki, T.: A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics, 6: 395-401 (1996).
71. Zhang, W. Y., Tu, Y. B., Haining, R. L. and Yu, A. M.: Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 isozymes. Drug Metab. Dispos., 37: 1-4 (2009).
72. Allorge, D., Breant, D., Harlow, J., Chowdry, J., Lo-Guidice, J. M., Chevalier, D., Cauffiez, C., Lhermitte, M., Blaney, F. E., Tucker, G. T., Broly, F. and Ellis, S. W.: Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. Proteins, 59: 339-346 (2005).
73. Allorge, D., Harlow, J., Boulet, O., Hayhurst, G. P., Chowdry, J., Roth, E., Crewe, K., Lo-Guidice, J. M., Lhermitte, M., Broly, F., Tucker, G. T. and Ellis, S. W.: In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism. Pharmacogenetics, 11: 739-741 (2001).
74. Toscano, C., Klein, K., Blievernicht, J., Schaeffeler, E., Saussele, T., Raimundo, S., Eichelbaum, M., Schwab, M. and Zanger, U. M.: Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP2988G>A: evidence for modulation of splicing events. Pharmacogenet. Genomics, 16: 755-766 (2006).
75. Klein, K., Tatzel, S., Raimundo, S., Saussele, T., Hustert, E., Pleiss, J., Eichelbaum, M. and Zanger, U. M.: A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6. Drug Metab. Dispos., 35: 1247-1250 (2007).
76. Kaminsky, L. S., de Morais, S. M., Faletto, M. B., Dunbar, D. A. and Goldstein, J. A.: Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol. Pharmacol., 43: 234-239 (1993).
77. Veronese, M. E., Doecke, C. J., Mackenzie, P. I., McManus, M. E., Miners, J. O., Rees, D. L., Gasser, R., Meyer, U. A. and Birkett, D. J.: Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem. J., 289(Pt 2): 533-538 (1993).
78. Rettie, A. E., Wienkers, L. C., Gonzalez, F. J., Trager, W. F. and Korzekwa, K. R.: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics, 4: 39-42 (1994).
79. Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z. Y., Kaminsky, L. S., Shenfield, G. M., Miners, J. O., Birkett, D. J. and Goldstein, J. A.: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6: 341-349 (1996).
80. Chang, T. K., Yu, L., Goldstein, J. A. and Waxman, D. J.: Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics, 7: 211-221 (1997).
81. Kumar, G. N., Dubberke, E., Rodrigues, A. D., Roberts, E. and Dennisen, J. F.: Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab. Dispos., 25: 110-115 (1997).
82. Yamazaki, H., Inoue, K., Chiba, K., Ozawa, N., Kawai, T., Suzuki, Y., Goldstein, J. A., Guengerich, F. P. and Shimada, T.: Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem. Pharmacol., 56: 243-251 (1998).
83. Rettie, A. E., Haining, R. L., Bajpai, M. and Levy, R. H.: A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res., 35: 253-255 (1999).
84. Yasar, U., Tybring, G., Hidestrand, M., Oscarson, M., Ingelman- Sundberg, M., Dahl, M. L. and Eliasson, E.: Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab. Dispos., 29: 1051-1056 (2001).
85. Tang, C., Shou, M., Rushmore, T. H., Mei, Q., Sandhu, P., Woolf, E. J., Rose, M. J., Gelmann, A., Greenberg, H. E., De Lepeleire, I., Van Hecken, A., De Schepper, P. J., Ebel, D. L., Schwartz, J. I. and Rodrigues, A. D.: In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics, 11: 223-235 (2001).
86. Sandberg, M., Yasar, U., Stromberg, P., Hoog, J. O. and Eliasson, E.: Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br. J. Clin. Pharmacol., 54: 423-429 (2002).
87. Thijssen, H. H. and Ritzen, B.: Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin. Pharmacol. Ther., 74: 61-68 (2003).
88. Lundblad, M. S., Stark, K., Eliasson, E., Oliw, E. and Rane, A.: Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem. Biophys. Res. Commun., 327: 1052-1057 (2005).
89. Bland, T. M., Haining, R. L., Tracy, T. S. and Callery, P. S.: CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem. Pharmacol., 70: 1096-1103 (2005).
90. Hanatani, T., Fukuda, T., Ikeda, M., Imaoka, S., Hiroi, T., Funae, Y. and Azuma, J.: CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenomics J., 1: 288-292 (2001).
91. Dickmann, L. J., Rettie, A. E., Kneller, M. B., Kim, R. B., Wood, A. J., Stein, C. M., Wilkinson, G. R. and Schwarz, U. I.: Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol. Pharmacol., 60: 382-387 (2001).
92. Tracy, T. S., Hutzler, J. M., Haining, R. L., Rettie, A. E., Hummel, M. A. and Dickmann, L. J.: Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab. Dispos., 30: 385-390 (2002).
93. Hanatani, T., Fukuda, T., Onishi, S., Funae, Y. and Azuma, J.: No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3. Eur. J. Clin. Pharmacol., 59: 233-235 (2003).
94. Guo, Y., Wang, Y., Si, D., Fawcett, P. J., Zhong, D. and Zhou, H.: Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica, 35: 853-861 (2005).
95. Guo, Y., Zhang, Y., Wang, Y., Chen, X., Si, D., Zhong, D., Fawcett, J. P. and Zhou, H.: Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab. Dispos., 33: 749-753 (2005).
96. Ieiri, I., Tainaka, H., Morita, T., Hadama, A., Mamiya, K., Hayashibara, M., Ninomiya, H., Ohmori, S., Kitada, M., Tashiro, N., Higuchi, S. and Otsubo, K.: Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using singlestrand conformation polymorphism analysis. Ther. Drug Monit., 22: 237-244 (2000).
97. Blaisdell, J., Jorge-Nebert, L. F., Coulter, S., Ferguson, S. S., Lee, S. J., Chanas, B., Xi, T., Mohrenweiser, H., Ghanayem, B. and Goldstein, J. A.: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics, 14: 527-537 (2004).
98. DeLozier, T. C., Lee, S. C., Coulter, S. J., Goh, B. C. and Goldstein, J. A.: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J. Pharmacol. Exp. Ther., 315: 1085-1090 (2005).
99. Herman, D., Dolzan, V. and Ingelman-Sundberg, M.: Characterization of the novel defective CYP2C9*24 allele. Drug Metab. Dispos., 35: 831-834 (2007).
100. Maekawa, K., Fukushima-Uesaka, H., Tohkin, M., Hasegawa, R., Kajio, H., Kuzuya, N., Yasuda, K., Kawamoto, M., Kamatani, N., Suzuki, K., Yanagawa, T., Saito, Y. and Sawada, J.: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet. Genomics, 16: 49-514 (2006).
101. Yin, T., Maekawa, K., Kamide, K., Saito, Y., Hanada, H., Miyashita, K., Kokubo, Y., Akaiwa, Y., Otsubo, R., Nagatsuka, K., Otsuki, T., Horio, T., Takiuchi, S., Kawano, Y., Minematsu, K., Naritomi, H., Tomoike, H., Sawada, J. and Miyata, T.: Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens. Res., 31: 1549-1557 (2008).
102. Lee, S. J., Kim, W. Y., Kim, H., Shon, J. H., Lee, S. S. and Shin, J. G.: Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab. Dispos., 37: 2262-2269 (2009).
103. Ibeanu, G. C., Blaisdell, J., Ghanayem, B. I., Beyeler, C., Benhamou, S., Bouchardy, C., Wilkinson, G. R., Dayer, P., Daly, A. K. and Goldstein, J. A.: An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics, 8: 129-136 (1998).
104. Ibeanu, G. C., Goldstein, J. A., Meyer, U., Benhamou, S., Bouchardy, C., Dayer, P., Ghanayem, B. I. and Blaisdell, J.: Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J. Pharmacol. Exp. Ther., 286: 1490-1495 (1998).
105. Ibeanu, G. C., Blaisdell, J., Ferguson, R. J., Ghanayem, B. I., Brosen, K., Benhamou, S., Bouchardy, C., Wilkinson, G. R., Dayer, P. and Goldstein, J. A.: A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J. Pharmacol. Exp. Ther., 290: 635-640 (1999).
106. Blaisdell, J., Mohrenweiser, H., Jackson, J., Ferguson, S., Coulter, S., Chanas, B., Xi, T., Ghanayem, B. and Goldstein, J. A.: Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics, 12: 703-711 (2002).
107. Hanioka, N., Tsuneto, Y., Saito, Y., Sumada, T., Maekawa, K., Saito, K., Sawada, J. and Narimatsu, S.: Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population. Xenobiotica, 37: 342-355 (2007).
108. Hanioka, N., Tsuneto, Y., Saito, Y., Maekawa, K., Sawada, J. and Narimatsu, S.: Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: in vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae. Basic Clin. Pharmacol. Toxicol., 102: 388-393 (2008).
109. Wang, J., Sonnerborg, A., Rane, A., Josephson, F., Lundgren, S., Stahle, L. and Ingelman-Sundberg, M.: Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics, 16: 191-198 (2006).